Plazomicin Sulfate Patent Expiration
Plazomicin Sulfate is Used for treating bacterial infections. It was first introduced by Cipla Usa Inc
Plazomicin Sulfate Patents
Given below is the list of patents protecting Plazomicin Sulfate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zemdri | US8383596 | Antibacterial aminoglycoside analogs | Jun 25, 2032 | Cipla Usa |
| Zemdri | US8822424 | Antibacterial aminoglycoside analogs | Nov 21, 2028 | Cipla Usa |
| Zemdri | US9266919 | Antibacterial aminoglycoside analogs | Nov 21, 2028 | Cipla Usa |
| Zemdri | US9688711 | Antibacterial aminoglycoside analogs | Nov 21, 2028 | Cipla Usa |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Plazomicin Sulfate's patents.
Latest Legal Activities on Plazomicin Sulfate's Patents
Given below is the list recent legal activities going on the following patents of Plazomicin Sulfate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 27 Dec, 2024 | US9688711 |
| Withdrawal of Application for PTE | 19 Dec, 2024 | US8822424 |
| Notice of Final Determination -Eligible | 19 Dec, 2024 | US8383596 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Aug, 2024 | US8383596 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 22 Aug, 2024 | US8822424 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 22 Aug, 2024 | US8383596 |
| Notice of Final Determination -Election Required | 23 Jul, 2024 | US8822424 |
| Notice of Final Determination -Election Required | 23 Jul, 2024 | US8383596 |
| FDA Final Eligibility Letter Critical
| 30 Jan, 2024 | US8822424 |
| FDA Final Eligibility Letter Critical
| 30 Jan, 2024 | US8383596 |
Plazomicin Sulfate's Family Patents
